In a phase II study, the VEGFR inhibitor bevacizumab combined with gemcitabine-capecitabine failed to show significant clinical improvement (mPFS: 8.1 months, mOS: 10.2 months) in CCA patients (Supplementary Table S1) [97]. The gene discussed is KDR; the disease is cholangiocarcinoma.